Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes
- PMID: 28940010
- DOI: 10.1007/s00210-017-1422-z
Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes
Abstract
Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. OM was reported to increase left ventricular ejection fraction and systolic ejection time, but little is known about the effect of heart rate on the action of OM. The present study, therefore, was designed to investigate the effects of OM on unloaded cell shortening and intracellular Ca2+ ([Ca2+]i) transients as a function of the pacing frequency. Isolated cardiomyocytes were stimulated at various frequencies under steady-state conditions. Cell length was monitored by an optical edge detector and changes in [Ca2+]i were followed using the Ca2+-sensitive dye Fura-2. At the pacing frequency of 1 Hz, OM (1-10 μM) significantly decreased both diastolic and systolic cell length, however, fractional shortening was augmented only by 1 μM OM. Time to peak tension and time of 90% relaxation were progressively increased by OM. At the frequency of 2 Hz, diastolic cell length was reduced by 10 μM OM to a larger extent than systolic cell length, resulting in a significantly decreased fractional shortening under these conditions. OM had no effect on the parameters of the [Ca2+]i transient at any pacing frequency. The results suggest that supratherapeutic concentrations of OM may decrease rather than increase the force of cardiac contraction especially in tachycardic patients.
Keywords: Cardiac myocytes; Cell shortening; Cytosolic Ca2+; Myosin activators; Omecamtiv mecarbil.
Similar articles
-
Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.Basic Res Cardiol. 2021 Apr 12;116(1):24. doi: 10.1007/s00395-021-00866-8. Basic Res Cardiol. 2021. PMID: 33844095 Free PMC article.
-
Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes.J Physiol Pharmacol. 2016 Aug;67(4):483-489. J Physiol Pharmacol. 2016. PMID: 27779469
-
Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.Pharmacol Res Perspect. 2020 Oct;8(5):e00656. doi: 10.1002/prp2.656. Pharmacol Res Perspect. 2020. PMID: 32969560 Free PMC article.
-
Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.Curr Med Chem. 2018;25(15):1720-1728. doi: 10.2174/0929867325666171222164320. Curr Med Chem. 2018. PMID: 29278207 Review.
-
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.Expert Opin Investig Drugs. 2016;25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19. Expert Opin Investig Drugs. 2016. PMID: 26587768 Review.
Cited by
-
Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency.Stem Cell Reports. 2020 Feb 11;14(2):312-324. doi: 10.1016/j.stemcr.2019.12.011. Epub 2020 Jan 16. Stem Cell Reports. 2020. PMID: 31956082 Free PMC article.
-
The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications.Circ Res. 2020 Jan 31;126(3):395-412. doi: 10.1161/CIRCRESAHA.119.315891. Epub 2020 Jan 30. Circ Res. 2020. PMID: 31999537 Free PMC article. Review.
-
Effects of Sarcolemmal Background Ca2+ Entry and Sarcoplasmic Ca2+ Leak Currents on Electrophysiology and Ca2+ Transients in Human Ventricular Cardiomyocytes: A Computational Comparison.Front Physiol. 2022 Jun 16;13:916278. doi: 10.3389/fphys.2022.916278. eCollection 2022. Front Physiol. 2022. PMID: 35784869 Free PMC article.
-
Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil's in vivo cardiac effects.J Gen Physiol. 2025 Jul 7;157(4):e202513762. doi: 10.1085/jgp.202513762. Epub 2025 Jun 18. J Gen Physiol. 2025. PMID: 40531056
-
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.Front Cardiovasc Med. 2024 Mar 19;11:1337154. doi: 10.3389/fcvm.2024.1337154. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38566963 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous